Mr. Andre Larente reports

DIAGNOS TO EXTEND EXERCISE PERIOD OF STOCK WARRANTS EXPIRING ON NOVEMBER 9, 2025

Diagnos Inc. intends to extend the exercise period of an aggregate of 1,125,000 stock warrants, issued as part of a non-brokered private placement of units initially announced on May 9, 2024, and set to expire on Nov. 9, 2025.

Subject to the TSX Venture Exchange consent, the extended expiry date shall be Aug. 5, 2026. All other provisions of the warrants, such as the warrant exercise price of 40 cents per common share of the corporation, will remain unchanged and fully in effect during the extended exercise period.

The corporation will issue a follow-up press release solely in the case where the exchange rejects the application for the amendment.

All moneys quoted in this press release shall be stated in lawful money of Canada.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging artificial intelligence, Diagnos aims to provide more information to health care clinicians to enhance diagnostic accuracy, streamline workflows and improve patient outcomes on a global scale.

We seek Safe Harbor.